Please assess the completion status of the following clinical trial:

Trial Title: Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate with bone metastases~* Treatment decision for Radium-223 according to local label needs to be made independent from and before patient enrollment in the study by the investigator~* No contra-indications according to the local marketing authorization~Exclusion Criteria:~* Previously treated with Radium-223 for any reason~* Currently treated in clinical trials including other Radium-223 studies or planned participation in an investigational program with interventions outside of routine clinical practice during the study period

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRPC patients (Type: None): Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan

Based on this trial design, predict the completion outcome and termination type (if applicable).